[1]
Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. European heart journal. 2010 Jul:31(13):1551-3. doi: 10.1093/eurheartj/ehq111. Epub 2010 May 3
[PubMed PMID: 20439260]
[2]
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology. 2009 Jul 14:54(3):220-8. doi: 10.1016/j.jacc.2009.05.006. Epub
[PubMed PMID: 19589434]
[3]
Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet (London, England). 2017 Mar 25:389(10075):1253-1267. doi: 10.1016/S0140-6736(16)31321-6. Epub 2016 Nov 30
[PubMed PMID: 27912983]
[4]
Shirani J,Pick R,Roberts WC,Maron BJ, Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. Journal of the American College of Cardiology. 2000 Jan;
[PubMed PMID: 10636256]
[5]
Briguori C, Betocchi S, Romano M, Manganelli F, Angela Losi M, Ciampi Q, Gottilla R, Lombardi R, Condorelli M, Chiariello M. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. The American journal of cardiology. 1999 Aug 1:84(3):309-15
[PubMed PMID: 10496441]
[6]
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 Mar 13:287(10):1308-20
[PubMed PMID: 11886323]
Level 1 (high-level) evidence
[7]
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European heart journal. 2014 Oct 14:35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29
[PubMed PMID: 25173338]
[8]
Gersh BJ,Maron BJ,Bonow RO,Dearani JA,Fifer MA,Link MS,Naidu SS,Nishimura RA,Ommen SR,Rakowski H,Seidman CE,Towbin JA,Udelson JE,Yancy CW, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. The Journal of thoracic and cardiovascular surgery. 2011 Dec;
[PubMed PMID: 22093723]
Level 1 (high-level) evidence
[9]
Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Journal of the American College of Cardiology. 2015 May 12:65(18):1915-28. doi: 10.1016/j.jacc.2015.02.061. Epub
[PubMed PMID: 25953744]
Level 3 (low-level) evidence
[10]
Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RHM, Lesser JR, Maron BJ. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2016 Mar 29:67(12):1399-1409. doi: 10.1016/j.jacc.2016.01.023. Epub
[PubMed PMID: 27012399]
Level 3 (low-level) evidence
[11]
Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, Maron MS. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation. 2016 Jan 5:133(1):62-73. doi: 10.1161/CIRCULATIONAHA.115.017633. Epub 2015 Oct 30
[PubMed PMID: 26518766]
Level 3 (low-level) evidence
[12]
Veselka J,Zemánek D,Tomasov P,Homolová S,Adlová R,Tesar D, Complications of low-dose, echo-guided alcohol septal ablation. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography
[PubMed PMID: 20014165]
[13]
Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2010 Feb 23:55(8):823-34. doi: 10.1016/j.jacc.2009.09.047. Epub
[PubMed PMID: 20170823]
Level 1 (high-level) evidence
[14]
Elesber A, Nishimura RA, Rihal CS, Ommen SR, Schaff HV, Holmes DR Jr. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. The American journal of cardiology. 2008 Feb 15:101(4):516-20. doi: 10.1016/j.amjcard.2007.09.111. Epub 2007 Dec 20
[PubMed PMID: 18312769]
[15]
Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet (London, England). 1995 Jul 22:346(8969):211-4
[PubMed PMID: 7616800]
[16]
Fernandes VL,Nielsen C,Nagueh SF,Herrin AE,Slifka C,Franklin J,Spencer WH 3rd, Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC. Cardiovascular interventions. 2008 Oct;
[PubMed PMID: 19463359]
[17]
Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Køber L, Endresen K, Eriksson MJ, Jørgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circulation. Cardiovascular interventions. 2011 Jun:4(3):256-65. doi: 10.1161/CIRCINTERVENTIONS.110.959718. Epub 2011 May 3
[PubMed PMID: 21540441]
Level 2 (mid-level) evidence
[18]
Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2005 Aug 2:46(3):470-6
[PubMed PMID: 16053960]
[19]
Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012 Nov 13:126(20):2374-80. doi: 10.1161/CIRCULATIONAHA.111.076257. Epub 2012 Oct 17
[PubMed PMID: 23076968]